Antiviral/Covid-19 Therapy
Please include your email.
Pro-rata portion of total principal value raised; Notes will be sold in increments of $1.00 with a minimum investment of $100.00.
About Medior is a biosciences company seeking to repurpose existing antiviral medications to treat SARS-CoV-2 (Covid-19). We are working on modifications in delivery format to use a known therapy to combat a novel virus. Reasons to Invest New drug development takes years and substantial capital investment; Repurposing existing therapies is faster and a fraction of the...
Have you done enough research to provide a rating? This is important for your fellow investors.
We only allow one revision to each rating category. Be sure about any changes.
No reports have been submitted
Contact support@crowdlustro.com if you need assistance.
Your experience on this site will be improved by allowing cookies.
